Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Shanghai ZJ Bio-Tech Co's Debt-to-Equity or its related term are showing as below:
SHSE:688317'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0 Max: 0.09
Current: 0.09
During the past 13 years, the highest Debt-to-Equity Ratio of Shanghai ZJ Bio-Tech Co was 0.09. The lowest was 0.00. And the median was 0.00.
SHSE:688317's Debt-to-Equity is ranked better than 70.03% of 704
companies
in the Medical Devices & Instruments industry
Industry Median: 0.23
vs SHSE:688317: 0.09
Shanghai ZJ Bio-Tech Co (SHSE:688317) Debt-to-Equity Explanation
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Shanghai ZJ Bio-Tech Co Debt-to-Equity Related Terms
Shanghai ZJ Bio-Tech Co Debt-to-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:688317 vs ABT, SYK, MDT: Debt-to-Equity Comparison
For the Medical Devices subindustry, Shanghai ZJ Bio-Tech Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai ZJ Bio-Tech Co Debt-to-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Shanghai ZJ Bio-Tech Co's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Shanghai ZJ Bio-Tech Co's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai ZJ Bio-Tech Co (SHSE:688317) has a Debt-to-Equity of 0.09 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Shanghai ZJ Bio-Tech Co and its competitors. According to the industry distribution chart, Shanghai ZJ Bio-Tech Co ranks #211 out of 704 companies in the Medical Devices & Instruments industry, placing it in the top 30%.
Is Shanghai ZJ Bio-Tech Co's Debt-to-Equity too high?
Shanghai ZJ Bio-Tech Co's current Debt-to-Equity is 0.09. The Medical Devices & Instruments industry median Debt-to-Equity is 0.23. Shanghai ZJ Bio-Tech Co's value of 0.09 is 60.9% below this industry median. Based on the distribution chart, Shanghai ZJ Bio-Tech Co ranks #211 out of 704 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Shanghai ZJ Bio-Tech Co has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai ZJ Bio-Tech Co's Debt-to-Equity compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Shanghai ZJ Bio-Tech Co ranks #211 out of 704 companies for Debt-to-Equity. This puts Shanghai ZJ Bio-Tech Co in the upper half of its industry. The industry median Debt-to-Equity is 0.23. Shanghai ZJ Bio-Tech Co's value of 0.09 is 60.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Devices & Instruments company?
The median Debt-to-Equity among Medical Devices & Instruments companies is 0.23, based on 704 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shanghai ZJ Bio-Tech Co's current Debt-to-Equity of 0.09 is 60.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Shanghai ZJ Bio-Tech Co and its competitors. For the Medical Devices & Instruments industry, the median Debt-to-Equity is 0.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai ZJ Bio-Tech Co's current Debt-to-Equity is 0.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai ZJ Bio-Tech Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai ZJ Bio-Tech Co (SHSE:688317) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥9.82, compared to a current price of ¥15.61 — trading 59% above its estimated fair value. The current Debt-to-Equity is 0.09 and 60.9% below the Medical Devices & Instruments industry median of 0.23. Shanghai ZJ Bio-Tech Co's overall GF Score™ is 60/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Shanghai ZJ Bio-Tech Co (SHSE:688317), the current Debt-to-Equity is 0.09 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai ZJ Bio-Tech Co (SHSE:688317) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai ZJ Bio-Tech Co stock appears to be overvalued.
The current stock price of ¥15.61 is trading 59% above its estimated GF Value™ of ¥9.82.
GuruFocus considers Shanghai ZJ Bio-Tech Co to be Significantly Overvalued.
Key valuation signals for SHSE:688317:
Debt-to-Equity: 0.09
GF Value™: ¥9.82 vs. price of ¥15.61 (59% above fair value)
Industry Position: 60.9% below the Medical Devices & Instruments median (#211 of 704)
No single metric tells the full story. See the SHSE:688317 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai ZJ Bio-Tech Co Ltd is engaged in research and development, production and sales of genetic diagnostic reagents and instruments and equipment. The rapid real-time fluorescent PCR diagnostic test reagents developed by the company are mainly used in clinical medicine, public health emergencies, entry-exit inspection and quarantine, food inspection, animal husbandry, aquaculture and other fields.
60GF Score
Get the complete analysis for SHSE:688317
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688317 has been successfully added to your 
